Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Paclitaxel
68
CHF
CHF 68.00
In stock
CDX-P0188-M01010 mgCHF 68.00
CDX-P0188-M05050 mgCHF 177.00
| Product Details | |
|---|---|
| Synonyms | Taxol; BMS 181339-01; NSC 125973 |
| Product Type | Chemical |
| Properties | |
| Formula |
C47H51NO14 |
| MW | 853.91 |
| CAS | 33069-62-4 |
| Source/Host Chemicals | Synthetic. |
| Purity Chemicals | ≥98% (NMR) |
| Appearance | White to off-white powder. |
| Solubility | Soluble in DMSO (50 mg/ml), methanol (50 mg/ml) or ethanol. |
| Identity | Determined by NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | RCINICONZNJXQF-MZXODVADSA-N |
| Smiles | O[C@](C(C)(C)C1=C(C)[C@H]2OC([C@@H]([C@H](C3=CC=CC=C3)NC(C4=CC=CC=C4)=O)O)=O)(C2)[C@H]([C@]([C@]([C@@H](O)C5)(C)C([C@@H]1OC(C)=O)=O)([H])[C@]6([C@]5([H])OC6)OC(C)=O)OC(C7=CC=CC=C7)=O |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | +4°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at +4°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
Anticancer compound. Chemotherapeutic used in patients with cancer and advanced forms of Kaposi's sarcoma. Microtubule assembly stabilizer. Reversibly binds to polymerized tubulin. Mitotic spindle assembly, chromosome segregation and cell division inhibitor. Induces cell cycle arrest at the G2/M phase. Apoptosis inducer through aberrant activation of cyclin-dependent kinases (CKDs) and the c-Jun N-terminal kinase/stress activated protein kinase (JNK/SAPK). Immunosuppressor, immunostimulant and TRAIL sensitizer.
Product References
(1) J.E. Liebmann, et al.; Br. J. Cancer 68, 1104 (1993) | (2) R. Foa, et al.; Int. J. Clin. Lab. Res. 24, 6 (1994) (Review) | (3) M. Woods, et al.; Mol. Med. 1, 506 (1995) | (4) A. Jordan, et al.; Med. Res. Rev. 18, 259 (1998) | (5) L.A. Amos & J. Löwe; Chem. Biol. 6, R65 (1999) (Review) | (6) M.V. Blagosklonny & T. Fojo; Int. J. Cancer 83, 151 (1999) | (7) T.H. Wang, et al.; J. Biol. Chem. 274, 8208 (1999) | (8) T.H. Wang, et al.; Cancer 88, 2619 (2000) | (9) T.M. Mekhail & M. Markman; Expert Opin. Pharmacother. 3, 755 (2002) | (10) A. Javeed, et al.; Eur. J. Pharm. Sci. 38, 283 (2009) (Review) | (11) D. Finlay, et al.;PLoS One 5, e13375 (2010) | (12) B. Ai, et al.; Am. J. Cancer Res. 6, 1624 (2016) (Review)
Related Products
